Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where O. Brodin is active.

Publication


Featured researches published by O. Brodin.


Lung Cancer | 2002

Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients

D. Brattström; Michael Bergqvist; Patrik Hesselius; Anders Larsson; Kristina Lamberg; Johan Wernlund; O. Brodin; Gunnar Wagenius

We have analysed the predictive and prognostic information in preoperatively collected serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients clinically evaluated as operable non-small cell lung cancer (NSCLC). Fifty-eight patients with operable NSCLC were included. VEGF and bFGF levels in serum were analysed using enzyme linked immunosorbent assays (Quantikine human VEGF and Quantikine HS human FGF basic, R&D Systems). Univariate analysis demonstrated that tumour volume, platelet counts, VEGF and bFGF were significant prognostic factors. However, only bFGF remained significant in the multivariate analysis (P=0.014). Significant correlations were demonstrated between VEGF levels and tumour volume (r=0.33; P=0.012) and platelet count (r=0.43; P=0.001). bFGF levels correlated significant with recurrent disease (r=0.34; P=0.01), platelet count (r=0.53, P<0.001) and performance status (r=0.29; P=0.029). Furthermore, bFGF levels and VEGF levels correlated significantly (r=0.44; P<0.001). We conclude that elevated circulating angiogenic cytokines correlate with tumour volume, higher relapse risk and poorer survival in patients with operable non-small cell lung cancer.


Lung Cancer | 1997

633 p53 gene mutations and p53 nuclear immunostaining in non-small lung cancer associated with clinical data

D. Brattström; Michael Bergqvist; Kristina Lamberg; G. Gustavsson; L. Scheibenflug; Gunnar Wagenius; M. Inganäs; O. Brodin

p53 gene mutations and p53 nuclear immunostaining in non-small cell lung cancer associated with clinical data.


Lung Cancer | 1997

516 Palliative radiation with two fractionation schedules of brain metastases from lung cancer

Gunnar Wagenius; M. Berqvist; D. Brattström; Helge Bennmarker; O. Brodin

Palliative radiation with two fractionation schedules of brain metastases from lung cancer.


Lung Cancer | 1997

517 Micronucleus assay as a predictor of radiosensitivity: The results of in vitro studies on 4 cell lines

D. Brattström; Michael Bergqvist; Gunnar Wagenius; O. Brodin

Micronucleos assay as a predictor of radiosensitivity:the results of In Vitro studies on cell lines.


Lung Cancer | 1997

514 Radiation responsiveness of human lung cancer cell lines measured with a short term semiautomatic assay

Michael Bergqvist; D. Brattström; L. Lennartsson; Gunnar Wagenius; O. Brodin

BACKGROUND Fluorometric microculture cytotoxicity assay (FMCA) is a short-term semi-automatic method, based on dye-inclusion of surviving cells. The assay was developed for investigations of drug resistance on tumour cells from biopsy material. In the present study, this short-term assay was evaluated, regarding usefulness in determining radio-sensitivity. MATERIALS AND METHODS Eight human lung cancer cell lines were used. There were five small cell lung cancer (SCLC and three non-small cell lung cancer (NSCLC cell lines. Results were compared with the corresponding data derived from the clonogenic assay and/or the extrapolation method. RESULTS The surviving fraction (SF) after 2, 5 and 10 Gy compared with data from the clonogenic assay were not in accordance for 5 of the 8 cell lines. The FMCA assay overestimated SF- values for the SCLC cell lines. CONCLUSION The FMCA assay is not useful as a quick screening method for the radioresponsiveness in vitro of human tumour cell lines.


Anticancer Research | 2001

Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma

Ann-Sofi Bergqvist; Michael Bergqvist; Daniel Brattström; Patrik Hesselius; Anders Larsson; O. Brodin; Gunnar Wagenius


Anticancer Research | 2001

The frequency of micronuclei in lung cancer cell lines and their correlation to intrinsic radiation sensitivity

Arm-Sofi Bergqvist; Daniel Brattström; Michael Bergqvist; O. Brodin; Gunnar Wagenius; Lilianne Abramsson Zetterberg


Medical Science Monitor | 2004

Endothelial markers and circulating angiogenic factors and p53 may be potential markers for recurrence in surgically resected non-small cell lung cancer patients

D. Brattström; Michael Bergqvist; Kenneth Wester; Patrik Hesselius; Zhi-Ping Ren; Lena Scheibenpflug; Gunnar Wagenius; O. Brodin


Lung Cancer | 2005

P-065 The role of a cytokeratin assay measuring cytokeratins 8, 18 and 19 and its correlation to clinical parameters in patients with lung cancer

A. Klinga; Michael Bergqvist; D. Brattström; H. Goike; Patrik Hesselius; O. Brodin; Gunnar Wagenius


Lung Cancer | 2005

P-720 Fractionated irradiation in human lungcancer cell lines andprediction of the effect according to individual tumour data

Mattias Hedman; D. Brattström; Michael Bergqvist; O. Brodin

Collaboration


Dive into the O. Brodin's collaboration.

Top Co-Authors

Avatar

Gunnar Wagenius

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Brattström

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar

Patrik Hesselius

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kristina Lamberg

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Johan Wernlund

Uppsala University Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge